ストックスクリーナーアプリを入手
0.5063
15.07%
0.0663
アフターアワーズ：
.49
-0.0163
-3.22%
前日終値:
$0.44
開ける：
$0.46
24時間の取引高:
270.49K
Relative Volume:
0.73
時価総額：
$41.21M
収益：
$5.12M
当期純損益:
$-67.00M
株価収益率:
-0.3444
EPS:
-1.47
ネットキャッシュフロー:
$-38.94M
1週間 パフォーマンス:
+13.60%
1か月 パフォーマンス:
+4.61%
6か月 パフォーマンス:
-44.97%
1年 パフォーマンス:
-93.67%
1日の値動き範囲:
$0.429
$0.5166
1週間の範囲:
$0.3911
$0.5166
52週間の値動き範囲:
$0.3816
$11.41
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
名前
Verrica Pharmaceuticals Inc
セクター
電話
484-453-3300
住所
10 NORTH HIGH STREET, WEST CHESTER, PA
VRCA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
0.5063 | 41.21M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | アップグレード | Needham | Hold → Buy |
| 2023-03-22 | 開始されました | Jefferies | Buy |
| 2023-02-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-12-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-06-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-24 | 開始されました | Northland Capital | Outperform |
| 2020-03-24 | 開始されました | Needham | Buy |
| 2019-02-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Verrica Pharmaceuticals Inc (VRCA) 最新ニュース
Earnings To Watch: Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2025 Result - GuruFocus
Verrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate Update - MSN
Verrica Pharmaceuticals (VRCA) Expected to Announce Earnings on Tuesday - Defense World
Head-To-Head Comparison: KalVista Pharmaceuticals (NASDAQ:KALV) and Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
Verrica Pharmaceuticals at The Citizens JMP Life Sciences Conference: Strategic Developments in Dermatology - Investing.com Canada
Verrica Pharmaceuticals to Report First Quarter 2025 - GlobeNewswire
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 - The Manila Times
Renaissance Technologies LLC Grows Position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Verrica Pharmaceuticals CEO to Present at Citizens Life Sciences Conference - MSN
Invesco Ltd. Makes New $32,000 Investment in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Geode Capital Management LLC Purchases 21,789 Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York - GlobeNewswire
Exclusive: Verrica Pharmaceuticals CEO Takes Center Stage at Major Life Sciences Conference in NYC - Stock Titan
Verrica Pharmaceuticals to Present at Needham Healthcare Conference - MSN
GLP-1 Receptor Agonist Market Is Booming Worldwide 2025-2032: Verrica Pharmaceuticals, AbbVie Inc. - newstrail.com
Verrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical Officer - MSN
Verrica Pharmaceuticals (NASDAQ:VRCA) Earns "Neutral" Rating from HC Wainwright - MarketBeat
New Drug Application Submitted in Japan for Verrica Pharmaceuticals’ TO-208 - MSN
Needham & Company LLC Reiterates “Hold” Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
HC Wainwright Analysts Decrease Earnings Estimates for VRCA - Defense World
What is HC Wainwright’s Forecast for VRCA FY2028 Earnings? - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Receives “Neutral” Rating from HC Wainwright - Defense World
Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH - MSN
H.C. Wainwright maintains Neutral on Verrica stock after Q1 update By Investing.com - Investing.com Canada
Verrica Pharmaceuticals at Needham Conference: Strategic Restructuring and Growth By Investing.com - Investing.com Canada
Hold Rating on Verrica Pharmaceuticals Amid Liquidity Concerns and Uncertain Financial Strategy - TipRanks
In face of U.S. stock market selloff, shares of West Chester firm are on the rise - The Business Journals
Verrica Pharmaceuticals Reports Strong Demand-Led Growth In Ycanth® In Q1 2025 - marketscreener.com
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025 - The Manila Times
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in - GlobeNewswire
Record-Breaking Quarter: YCANTH Crosses 10K Units Milestone with 17% Growth - Stock Titan
Verrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of Directors - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now - MSN
Verrica Pharmaceuticals appoints new board member By Investing.com - Investing.com India
Verrica Pharmaceuticals appoints new board member - Investing.com Australia
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors - GlobeNewswire
Palvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology Congress - MyChesCo
Verrica Pharmaceuticals expands board with new director By Investing.com - Investing.com Canada
Verrica Pharmaceuticals Appoints Dr. Corcoran as Director - TipRanks
Verrica Pharmaceuticals expands board with new director - Investing.com
Strategic Move: Verrica Adds Formation Bio CDO to Board Amid YCANTH Success - Stock Titan
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Verrica Pharmaceuticals Inc (VRCA) 財務データ
収益
当期純利益
現金流量
EPS
4.10%
大文字化:
|
ボリューム (24 時間):